Lilly says weight loss drug cuts heart failure risk by 38% in trial

Trial results show Eli Lilly's (LLY.N) weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.
Shares of the drugmaker rose more than 3% in early trade.